The American Diabetes Association recognizes that the paradigm in diabetes care is shifting with PreventAGE Healthcare’s new, precise, and accurate diagnostic tests.
PreventAGE Health Care was founded with the goal of fundamentally improving diabetes care by providing patients and doctors with the necessary tools to predict and more effectively manage diabetic complications. Built on over two decades of complications-focused research, our unique technologies are built to provide individual risk profiles and stimulate development of therapeutic approaches to delay or arrest complications arising from diabetes.
For more information about PreventAGE Health Care, please visit their website.
Johnson & Johnson Innovation announced PreventAGE as the winner of the Singapore QuickFire Challenge in the area of Consumer Health
The Singapore QuickFire Challenge for Metabolic Disease Innovation was launched at BioPharma Asia in March 2017 in collaboration Johnson & Johnson Innovation a Division of Johnson & Johnson (China) Investment Ltd., ETPL, and Singapore-MIT Alliance for Research and Technology (SMART). The goal was to attract entrepreneurs, academics and biotech researchers from around the world to submit the best ideas, technologies, or solutions holding the potential to make a major difference for the millions of people in the Asia Pacific region and around the world who suffer from metabolic diseases, such as diabetes and obesity.
The Challenge received a total of 38 applications from 13 countries with solutions across the pharmaceuticals, medical device and consumer sectors. Three winners were each awarded SGD100,000 project money for research in Singapore, access to ETPL laboratory space, and one year of mentorship and coaching from Johnson & Johnson Innovation, ETPL and SMART.
The winner in the area of Consumer Health was New Hampshire-based PreventAGE Health Care, led by Paul Beisswenger, M.D., CSO and Mark Carvlin, Ph.D., President and COO. PreventAGE employs precision bioanalytical techniques, predictive analytics, and proprietary algorithms to alert patients with diabetes to their personal risk for developing specific complications. Patient data is analyzed to identify and quantify a panel of selected biomarkers that are correlated with specific, life-threatening complications. The data is further analyzed and compiled into a report which is used by physicians and patients to predict risk, personalize treatments, improve outcomes, and reduce healthcare costs for patients with diabetes.
“At Johnson & Johnson, we believe that a great idea can come from anywhere and anyone. The Singapore QuickFire Challenge reinforces our unique vision for collaboration in an open innovation model, where connections between researchers, investors, entrepreneurs and other stakeholders are facilitated as part of a global innovation network,” said Dong Wu, Head, Asia Pacific Innovation Center, Johnson & Johnson Innovation. “Our vision has really come to life.”